U.S. SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

 

INFORMATION REQUIRED IN PROXY STATEMENT

 

SCHEDULE 14A INFORMATION

 

PROXY STATEMENT PURSUANT TO SECTION 14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Filed by the Registrant  x

Filed by a Party other than the Registrant  o

 

Check the appropriate box:

 

o  Preliminary Proxy Statement

o  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

o  Definitive Proxy Statement

x  Definitive Additional Materials

o  Soliciting Material Pursuant to Rule 14a-12

 

 

Array BioPharma Inc.

 

(Name of Registrant as Specified in its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of filing fee (Check the appropriate box):

 

x     No fee required.

 

o       Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

 

(1)       Title of each class of securities to which transaction applies:

 

(2)       Aggregate number of securities to which transaction applies:

 

(3)       Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

(4)       Proposed maximum aggregate value of transaction:

 

(5)       Total fee paid:

 

o       Fee paid previously with preliminary materials

 

o       Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

 

(1)       Amount previously paid:

 

(2)       Form, schedule or registration statement no.:

 

(3)       Filing party:

 

(4)       Date filed:

 

 

 


 

*** Exercise Your Right to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Stockholder Meeting to Be Held on October 25, 2018. ARRAY BIOPHARMA INC. You are receiving this communication because you hold shares in the company named above. This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of ARRAY BIOPHARMA INC. 3200 WALNUT STREET BOULDER, CO 80301 the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side). We encourage you to access and review all of the important information contained in the proxy materials before voting. proxy materials and voting instructions. E50595-P12933 See the reverse side of this notice to obtain Meeting Information Meeting Type:Annual Meeting For holders as of:August 29, 2018 Date: October 25, 2018Time: 1:00 PM MDT Location: 1825 33rd Street Boulder, Colorado 80301

 


Before You Vote How to Access the Proxy Materials Have the information that is printed in the box marked by the arrow XXXX XXXX XXXX XXXX (located on the by the arrow XXXX XXXX XXXX XXXX (located on the following page) in the subject line. How To Vote Please Choose One of the Following Voting Methods marked by the arrow XXXX XXXX XXXX XXXX (located on the following page) available and follow the instructions. E50596-P12933 Vote In Person: Many stockholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares. Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card. Proxy Materials Available to VIEW or RECEIVE: ANNUAL REPORTNOTICE AND PROXY STATEMENT How to View Online: following page) and visit: www.proxyvote .com. How to Request and Receive a PAPER or E-MAIL Copy: If you want to receive a paper or e-mail copy of these documents, you must request one. There is NO charge for requesting a copy. Please choose one of the following methods to make your request: 1) BY INTERNET:www.proxyvote.com 2) BY TELEPHONE: 1-800-579-1639 3) BY E-MAIL*:sendmaterial@proxyvote.com * If requesting materials by e-mail, please send a blank e-mail with the information that is printed in the box marked Requests, instructions and other inquiries sent to this e-mail address will NOT be forwarded to your investment advisor. Please make the request as instructed above on or before October 11, 2018 to facilitate timely delivery.

 


1. Election of two Class III directors to serve for a three-year term of office expiring at the 2021 Annual Meeting of Stockholders. Nominees: 1a. Charles M. Baum, M.D., Ph.D. 1b. Gwen Fyfe, M.D. 2. Amendment of our Amended and Restated Certificate of Incorporation to increase the authorized shares of common stock from 280,000,000 to 340,000,000. 3. Advisory vote to approve the compensation of our named executive officers as disclosed in the accompanying Proxy Statement. 4. Ratification of the appointment of KPMG LLP as our independent registered public accountants for the fiscal year ending June 30, 2019. NOTE: Such other business as may properly come before the meeting or any adjournment thereof. The Board of Directors recommends a vote "For" all directors nominated for re-election and a vote "For" all other proposals. E50597-P12933 Voting Items

 


E50598-P12933